CRISPR Therapeutics AG ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für CRISPR Therapeutics AG zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um CRISPR Therapeutics AG zu Deinem Portfolio hinzuzufügen.
Curing disease, as opposed to just masking symptoms, is a big deal. CRISPR Therapeutics aims to cure by editing problem genes. So CRSP is the future of medicine! This approach can be too futuristic for many tastes. That, plus questions about CRSP's ability to scale production and make treatments affordable, have been like a cloud over the stock. But in June, CRSP picked up some big-time express...
When picking new stocks for your portfolio, your best bet is looking for companies that you can hold forever. It may take that long for an idea or a business premise to fully pay off!
There are many promising corporations that investors can buy on a dip due to recent market volatility or company-specific issues that predate this year. Take, for instance, CRISPR Therapeutics (CRSP 6.43%) and Viking Therapeutics (VKTX 3.94%), two mid-cap biotech companies that have lagged broader equities over the trailing-12-month period.
-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% in LDL, with a well-tolerated safety profile-
If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line.
The latest shake-up at the FDA forced out the top two officials in charge of reviewing cell and gene therapies, analysts said.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.